Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:

NCT ID: NCT02135029 Completed - Hyperlipidemia Clinical Trials

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

SPIRE-SI
Start date: June 2014
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.

NCT ID: NCT02130505 Completed - Clinical trials for Type 2 Diabetes Mellitus

Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes

INFORM
Start date: June 2007
Phase: N/A
Study type: Interventional

In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.

NCT ID: NCT02116517 Completed - Hyperlipidemia Clinical Trials

Effects of Green Tea Extract on Obese Women With High Level of LDL

GTE-LDL
Start date: August 2011
Phase: Phase 3
Study type: Interventional

Green tea is one of the most popular beverages in the world. It is believed to have beneficial effect in prevention and treatment of many diseases, one of which is reducing LDL-C. The aim of the study is to examine the effect of supplement containing GTE on obese with high LDL level.

NCT ID: NCT02100514 Completed - Hyperlipidemia Clinical Trials

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

SPIRE-LL
Start date: October 28, 2014
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.

NCT ID: NCT02100202 Not yet recruiting - Hyperlipidemia Clinical Trials

Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 days of intervention.

NCT ID: NCT02087540 Recruiting - Hypertension Clinical Trials

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Start date: May 2013
Phase: Phase 3
Study type: Interventional

To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.

NCT ID: NCT02064881 Recruiting - Type 2 Diabetes Clinical Trials

Efficacy Study of Metformin Glycinate on Postprandial Lipemia

Start date: October 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to evaluate the effect of metformin glycinate vs metformin hydrochloride on postprandial lipemia. 72 patients will be included, they will be randomized and assigned into one of the two treatment groups: metformin glycinate 1240 mg BID or metformin hydrochloride 1000 mg BID (36 patients per group). The patients will be followed for 4 months. Blood count, blood chemistry, liver profile, lipid profile, HbA1c, apolipoprotein B, oxidized LDL, fibroblast growth factor 21, leptin, adiponectin, C-reactive protein, free fatty acids, fibrinogen, Goodpasture Binding Protein (GPBP) and antioxidant activity of plasma will be measured at baseline and 4 months. Additionally, after a structured meal, the following parameters will be measured: glucose, insulin, triglycerides, apolipoprotein B and oxidized LDL. (baseline and 4 months). Throughout the study adverse events will be documented.

NCT ID: NCT02056847 Completed - Clinical trials for HbA1c Level Associated With Lipid Compositions

to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia

SIPHON
Start date: September 2013
Phase: Phase 4
Study type: Interventional

Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)

NCT ID: NCT02047175 Completed - Hypertension Clinical Trials

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)

NCT ID: NCT02044627 Completed - Hyperlipidemia Clinical Trials

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Start date: December 2013
Phase: Phase 1
Study type: Interventional

This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of [14C]-ETC-1002